Keratinocyte dysfunction in vitiligo epidermis: Cytokine microenvironment and correlation to keratinocyte apoptosis

Histology and Histopathology

Volumn 24, Issue 7, 2009, Pages 849-857

  Moretti, Silvia ^a   Fabbri, Paolo ^a   Baroni, Gianna ^a   Berti, Samantha ^a   Bani, Daniele ^a   Berti, Emilio ^b   Nassini, Romina ^a   Lotti, Torello ^a   Massi, Daniela ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

Apoptosis; Cytokines; Keratinocytes; Vitiligo

Indexed keywords

CYTOKINE; FLUORESCEIN ISOTHIOCYANATE; FLUORESCENT DYE; MESSENGER RNA;

ADOLESCENT; ADULT; APOPTOSIS; ARTICLE; BIOPSY; CASE CONTROL STUDY; CHEMISTRY; CHILD; EPIDERMIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; INFANT; KERATINOCYTE; MALE; MELANOCYTE; METABOLISM; NICK END LABELING; PATHOLOGY; PHYSIOLOGY; PRESCHOOL CHILD; ULTRASTRUCTURE; VITILIGO;

ADOLESCENT; APOPTOSIS; BIOPSY; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CYTOKINES; EPIDERMIS; FEMALE; FLUORESCEIN-5-ISOTHIOCYANATE; FLUORESCENT DYES; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; IN SITU NICK-END LABELING; INFANT; KERATINOCYTES; MALE; MELANOCYTES; RNA, MESSENGER; VITILIGO; YOUNG ADULT;

EID: 68849103736     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Anderson L. and Seilhamer J. (1997). A comparison of selected mRNA and protein abundances in human liver. Electrophoresis 18, 533-537.
2. Bhawan J. and Bhutani L.K. (1983). Keratinocyte damage in vitiligo. J. Cutan. Pathol. 10, 207-212.
3. Birol A., Kisa U., Kurtipek G.S., Kara F., Kocak M., Erkek E. and Caglayan O. (2006). Increased tumor necrosis factor alpha (TNFalpha) and interleukin 1 alpha (IL1-alpha) levels in the lesional skin of patients with nonsegmental vitiligo. Int. J. Dermatol. 45, 992-923.
4. Dell'Anna M.L. and Picardo M. (2006). A review and a new hypothesis for non-immunological pathogenetic mechanisms in vitiligo. Pigment Cell Res. 19, 406-411.
5. Grichnik J.M., Burch J.A., Burchette J. and Shea C.R. (1998). The SCF/KIT pathway plays a critical role in the control of normal human melanocyte homeostasis. J. Invest. Dermatol. 111, 233-238.
6. Grimes E.P., Morris R., Avaniss-Aghajani E., Soriano T., Meraz M. and Metger A. (2004). Topical tacrolimus therapy for vitiligo: therapeutic response and skin messenger RNA expression of proinflammatory cytokines. J. Am. Acad. Dermatol. 51, 52-61.
7. Halaban R., Langdon R., Birchall N., Cuono C., Baird A., Scott G., Moellmann G. and McGuire J. (1988). Bfgf from human keratinocytes is a natural mitogen for melanocytes. J. Cell Biol. 107, 1611-1619.
8. Hann S.K. and Nordlund J. (2000). Vitiligo. Blackwell Science. Oxford.
9. Imokawa G. (2004). Autocrine and paracrine regulation of melanocytes in human skin and in pigmentary disorders. Pigment Cell Res. 17, 96-110.
10. Imokawa G., Yada Y. and Miyagishi M. (1992). Endothelins secreted from human keratinocytes are intrinsic mitogens for human melanocytes. J. Biol. Chem. 267, 24675-24680.
11. Imokawa G., Yada Y., Kimura M. and Morisaki N. (1998). Granulocyte/macrophage colony-stimulating factor is an intrinsic keratinocytes-derived growth factor for human melanocytes in UVAinduced melanosis. Biochem. J. 313, 625-631.
12. Jimbow K. (1976). Some aspects of melanin biology: 1950-1975. J. Invest. Dermatol. 67, 72-78.
13. Kim N.H., Jeon S., Lee H.J. and Lee A.Y. (2007). Impaired PI3K/Akt activation-mediated NF-kappaB inactivation under elevated TNFalpha is more vulnerable to apoptosis in vitiliginous keratinocytes. J. Invest. Dermatol. 127, 2612-7261.
14. Kitamura R., Tsukamoto K., Harada K., Shimizu A., Shimada S., Kobayashi T. and Imokawa G. (2004). Mechanisms underlying the dysfunction of melanocytes in vitiligo epidermis: role of SCF/KIT protein interactions and its downstream effector, MITF-M. J. Pathol. 202, 463-475.
15. Lan C.C.E., Chen G.S., Choiou M.H., Wu C.S., Chang C.H. and Yu H.S. (2005). FK506 promotes melanocyte and melanoblast growth and creates a favourable milieu for cell migration via keratinocytes: possible mechanisms of how tacrolimus ointment induces repigmentation in patients with vitiligo. Br. J. Dermatol. 153, 498-505.
16. Lee A.Y., Youm Y.H., Kim N.H., Yang H. and Choi W.I. (2004). Keratinocytes in the depigmented epidermis of vitiligo are more vulnerable to trauma (suction) than keratinocytes in the normally pigmented epidermis, resulting in their apoptosis. Br. J. Dermatol. 151, 995-1003.
17. Lee A.Y., Kim N.H., Choi W.I. and Youm Y.H. (2005). Less keratinocytederived factors related to more keratinocyte apoptosis in depigmented than normally pigmented suction-blistered epidermis may cause passive melanocyte death in vitiligo. J. Invest. Dermatol. 124, 976-983.
18. Maresca V., Roccella M., Roccella F., Camera E., Del Porto G., Passi S., Grammatico P. and Picardo M. (1997). Increased sensitivity to peroxidative agents as a possible pathogenic factor for melanocyte damage in vitiligo. J. Invest. Dermatol. 109, 310-313.
19. Meng X., Sawamura D., Baba T., Ina S., Ita K., Tamai K., Hanada K. and Hashimoto I. (1999). Transgenic TNF-α causes apoptosis in epidermal keratinocytes after subcutaneous injection of TNF-α DNA plasmid. J. Invest. Dermatol. 113, 856-858.
20. Moellmann G., Klein-Angere S., Scollay D.A., Nordlund J.J. and Lerner A.B. (1982). Extracellular granular material and degeneration of keratinocytes in the normally pigmented epidermis of patients with vitiligo. J. Invest. Dermatol. 79, 321-330.
21. Moretti S., Spallanzani A., Amato L., Hautmann G., Gallerani I. and Fabbri P. (2002a). Vitiligo and epidermal microenvironment: possible involvement of keratinocytes-derived cytokines. Arch. Dermatol. 138, 273-274.
22. Moretti S., Spallanzani A., Amato L., Hautmann G., Gallerani I., Fabiani M. and Fabbri P. (2002b). New insights into the pathogenesis of vitiligo: imbalance of epidermal cytokines at sites of lesions. Pigment Cell Res. 15, 87-92.
23. Moretti S., Amato L., Bellandi S. and Fabbri P. (2006). Focus on vitiligo: a generalized skin disorder. Eur. J. Inflam. 4, 21-30.
24. Ongenae K., van Geel N. and Naeyaert J.M. (2003). Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res. 16, 90-100.
25. Reinartz J., Bechtel M.J. and Kramer M.D. (1996). Tumor necrosisalpha-induced apoptosis in a human keratinocyte cell line (HaCaT) is counteracted by transforming growth factor-alpha. Exp. Cell Res. 228, 334-340.
26. Rigopoulos D., Gregoriou S., Larias G., Moustou E., Belayeva-Karatza E. and Kalogeromitros D. (2007). Etanercept in the treatment of vitiligo. Dermatology 215, 84-85.
27. Singh Z.N., Tretiakova M.S., Shea C.R. and Petrnic-Rosic V.M. (2006). Decreased CD117 expression in hypopigmented mycosis fungoides correlates with hypomelanosis: lessons learned from vitiligo. Mod. Pathol. 19, 1255-1260.
28. Swope V.B., Abdel-Malek Z., Kassem L.M. and Nordlund J.J. (1991). Interleukin 1· and 6 and tumor necrosis factor a are paracrine inhibitors of human melanocyte proliferation and melanogenesis. J. Invest. Dermatol. 96, 180-185.